If (as a physics style thought experiment) the disease happens at the same rate in two populations, but is only diagnosed and treated in one population, then you'd naturally expect the untreated population to be, on average, somewhat less successful in attention-mandatory academics; math, sciences, computer programming... This would seem to be internally consistent, like a conspiracy theory, which is a heck of a long way from being proven in reality of course.
I've known quite a few people who would snort adderall and other amphetamines-based analogs as a study drug - they reported being able to remember things better, and to get into a single-minded, grinding mindset that sounds a lot like what we programmers strive to achieve as flow. Various mathematicians (notably Erdos) have used amphetamines as a nootropic.
As a counter thought experiment, what if we are giving amphetamines to one subset of the population at a much higher rate than the other, and these drugs act as a force-multiplier for effort directed towards flow-dependent activities, like programming, science, and mathematics?
The main treatment for ADHD is of course lifelong amphetamine prescriptions, and the US has a private pharmaceuticals industry very happy to market to insecure parents. And a general American insecurity about education that results in an astonishingly high proportion of elementary schoolers who get no or minimal recess at all.
The single biggest risk factors for an ADHD diagnosis are being male and being in the youngest quartile of your classroom. This is something we have managed to pathologize.
Coloquially known as ADD. The condition presents in different ways:
* Inactive: "ADD." Symptoms of innatention.
* Hyperactive-Impulse: Hyperactivity and implusiveness, but no innatention.
* Combined: "ADHD." Hyperactivity, impulsiveness and innatention.
The hyperactive variants are easier to diagnose, the first is often misdiagnosed as "your kid is lazy/stupid." It's possible that females have a lower chance to present with one of the hyperactivity variants.